Published in J Clin Microbiol on February 01, 2005
Sequence-based identification of filamentous basidiomycetous fungi from clinical specimens: a cautionary note. J Clin Microbiol (2009) 2.44
Fungal infections in primary immunodeficiencies. Eur J Pediatr (2007) 1.37
Clinical significance of filamentous basidiomycetes illustrated by isolates of the novel opportunist Ceriporia lacerata from the human respiratory tract. J Clin Microbiol (2012) 1.12
First human case of pulmonary fungal ball due to a Perenniporia species (a basidiomycete). J Clin Microbiol (2012) 0.99
Death by edible mushroom: first report of Volvariella volvacea as an etiologic agent of invasive disease in a patient following double umbilical cord blood transplantation. J Clin Microbiol (2010) 0.86
Filamentous Basidiomycetes in the Clinical Laboratory. Curr Fungal Infect Rep (2013) 0.82
Identification of Inonotus obliquus and analysis of antioxidation and antitumor activities of polysaccharides. Curr Microbiol (2008) 0.81
Phellinus tropicalis abscesses in a patient with chronic granulomatous disease. J Clin Immunol (2013) 0.79
Paravertebral mushroom: identification of a novel species of Phellinus as a human pathogen in chronic granulomatous disease. J Clin Microbiol (2014) 0.75
Use of potato flakes agar in clinical mycology. J Clin Microbiol (1982) 3.73
Identification of Aspergillus species using internal transcribed spacer regions 1 and 2. J Clin Microbiol (2000) 3.41
Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med (1981) 2.31
Brain abscess caused by Schizophyllum commune: an emerging basidiomycete pathogen. J Clin Microbiol (1996) 2.00
Ulceration of the palate caused by a basidiomycete Schizophyllum commune. Sabouraudia (1973) 1.85
Successful treatment of Paecilomyces varioti infection in a patient with chronic granulomatous disease and a review of Paecilomyces species infections. Clin Infect Dis (1992) 1.84
Diagnostic difficulties caused by a nonclamped Schizophyllum commune isolate in a case of fungus ball of the lung. J Clin Microbiol (1995) 1.71
Allergic bronchopulmonary mycosis caused by the basidiomycetous fungus Schizophyllum commune. Clin Infect Dis (1994) 1.68
Chronic maxillary sinusitis associated with the mushroom Schizophyllum commune in a patient with AIDS. Clin Infect Dis (1992) 1.67
Maxillary sinus infection caused by the homobasidiomycetous fungus Schizophyllum commune. J Clin Microbiol (1986) 1.59
The benomyl test as a fundamental diagnostic method for medical mycology. J Clin Microbiol (1993) 1.57
A basidiomycete probably causing onychomycosis. J Invest Dermatol (1950) 1.55
In vitro activities of approved and investigational antifungal agents against 44 clinical isolates of basidiomycetous fungi. Antimicrob Agents Chemother (2001) 1.42
Basidiomycetous (mushroom) infection of the maxillary sinus. Otolaryngol Head Neck Surg (1990) 1.33
Endocarditis caused by a Coprinus species: a fungus of the toadstool group. J Med Microbiol (1971) 1.32
Molecular characterization, relatedness and antifungal susceptibility of the basidiomycetous Hormographiella species and Coprinus cinereus from clinical and environmental sources. Antonie Van Leeuwenhoek (1996) 1.29
Disseminated infection due to Chrysosporium zonatum in a patient with chronic granulomatous disease and review of non-Aspergillus fungal infections in patients with this disease. J Clin Microbiol (1999) 1.27
Fatal pulmonary infection caused by the basidiomycete Hormographiella aspergillata. J Clin Microbiol (1997) 1.24
Bronchial mucoid impaction due to the monokaryotic mycelium of Schizophyllum commune. Clin Infect Dis (1996) 1.21
Rare fatal simultaneous mould infection of the lung caused by Aspergillus flavus and the basidiomycete Coprinus sp. in a leukemic patient. J Med Vet Mycol (1997) 1.18
Maxillary sinusitis caused by Schizophyllum commune and experience with treatment. J Med Vet Mycol (1998) 1.17
Proceedings towards a natural classification of the worldwide taxa Phellinus s.l. and Inonotus s.l., and phylogenetic relationships of allied genera. Mycologia (2010) 1.10
Successful treatment of systemic Exophiala dermatitidis infection in a patient with chronic granulomatous disease. Clin Infect Dis (1992) 1.10
[Chronic sinusitis caused by Schizophyllum commune in AIDS]. Presse Med (1993) 1.08
Maxillary sinusitis caused by medusoid form of Schizophyllum commune. J Clin Microbiol (1999) 1.07
Multifocal osteomyelitis caused by Paecilomyces varioti in a patient with chronic granulomatous disease. Infection (1995) 1.03
Rhizochaete, a new genus of phanerochaetoid fungi. Mycologia (2010) 1.01
Disseminated infection with Pseudallescheria boydii in a patient with chronic granulomatous disease: response to gamma-interferon plus antifungal chemotherapy. Pediatr Infect Dis J (1991) 1.00
The pathogenic potential of Sporotrichum pruinosum isolated from the human respiratory tract. J Med Vet Mycol (1988) 0.99
Acremonium strictum-related pulmonary infection in a patient with chronic granulomatous disease. J Infect Dis (1984) 0.98
Invasive infection with Sarcinosporon inkin in a patient with chronic granulomatous disease. Am J Clin Pathol (1990) 0.95
Pathogenicity of Sporotrichum pruninosum and Cladosporium oxysporum, isolated from the bronchial secretions of a patient, for laboratory mice. Mycopathologia (1992) 0.93
Paecilomyces lilacinus infection in a child with chronic granulomatous disease. J Infect (1992) 0.92
Amplification of mitochondrial small subunit ribosomal DNA of polypores and its potential for phylogenetic analysis. Mycologia (2010) 0.88
Successful medical therapy of Aspergillus osteomyelitis of the spine in an 11-year-old boy with chronic granulomatous disease. Pediatrics (1994) 0.84
Chronic bullous disease of childhood and a paecilomyces lung infection in chronic granulomatous disease. Arch Dis Child (1997) 0.83
Phellinus coronadensis: a new species from southern Arizona, USA. Mycologia (2010) 0.78
Studies in forest pathology; identification of cultures of wood-rotting fungi. Can J Res (1948) 0.78
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med (1991) 12.09
Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet (1992) 11.38
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Resistance of Candida species to fluconazole. Antimicrob Agents Chemother (1995) 9.04
Multicenter evaluation of four methods of yeast inoculum preparation. J Clin Microbiol (1988) 8.67
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell (1993) 6.83
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med (1996) 6.49
Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol (2000) 6.33
Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol (1995) 6.02
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
Ceftriaxone-resistant salmonella infection acquired by a child from cattle. N Engl J Med (2000) 4.68
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol (1994) 4.27
Bartonella-like erythrocyte inclusions in thrombotic thrombocytopenic purpura. Lancet (1997) 4.09
Repressing a repressor: gibberellin-induced rapid reduction of the RGA protein in Arabidopsis. Plant Cell (2001) 3.82
Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis (2001) 3.75
Use of potato flakes agar in clinical mycology. J Clin Microbiol (1982) 3.73
Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. J Clin Microbiol (1994) 3.62
Antifungal susceptibility testing. Current state of technology, limitations, and standardization. Infect Dis Clin North Am (1993) 3.55
Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol (1994) 3.46
Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol (1996) 3.42
Identification of Aspergillus species using internal transcribed spacer regions 1 and 2. J Clin Microbiol (2000) 3.41
Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts. J Clin Microbiol (1986) 3.40
Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis (1997) 3.27
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother (1993) 3.25
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother (1998) 3.00
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol (1990) 2.99
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol (2006) 2.86
In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol (1999) 2.82
Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. J Clin Microbiol (1994) 2.81
Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother (1988) 2.73
The DELLA motif is essential for gibberellin-induced degradation of RGA. Proc Natl Acad Sci U S A (2001) 2.72
Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol (1995) 2.66
Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol (1998) 2.65
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis (1998) 2.61
Congenital heart disease in mice deficient for the DiGeorge syndrome region. Nature (1999) 2.60
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis (1998) 2.56
Mycoses caused by Candida lusitaniae. Rev Infect Dis (1988) 2.53
Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates. J Clin Microbiol (1998) 2.48
Standardization of antifungal susceptibility testing. J Med Vet Mycol (1992) 2.43
Localization of putative stem cells in dental epithelium and their association with Notch and FGF signaling. J Cell Biol (1999) 2.39
Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J Clin Microbiol (1996) 2.28
In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother (1997) 2.27
Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm Res (2007) 2.21
Self-organization of periodic patterns by dissociated feather mesenchymal cells and the regulation of size, number and spacing of primordia. Development (1999) 2.20
Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol (2010) 2.19
Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol (2005) 2.18
Invasive aspergillosis. Rev Infect Dis (1984) 2.18
Emerging agents of phaeohyphomycosis: pathogenic species of Bipolaris and Exserohilum. J Clin Microbiol (1986) 2.17
Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother (2000) 2.13
Three distinct genotypes within Candida parapsilosis from clinical sources. J Clin Microbiol (1995) 2.13
Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother (1995) 2.12
Fluconazole-resistant Candida albicans. Clin Infect Dis (1993) 2.10
Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis (1993) 2.03
Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child. Clin Infect Dis (1998) 2.03
Spectrum of zygomycete species identified in clinically significant specimens in the United States. J Clin Microbiol (2009) 2.02
Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis (1997) 2.00
Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis (1996) 1.99
In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (1994) 1.95
Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother (1991) 1.91
Complete DiGeorge syndrome: persistence of profound immunodeficiency. J Pediatr (1998) 1.90
Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chemother (1989) 1.89
Multicenter comparison of a colorimetric microdilution broth method with the reference macrodilution method for in vitro susceptibility testing of yeast isolates. Diagn Microbiol Infect Dis (1994) 1.88
Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother (1993) 1.83
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother (1995) 1.77
Evaluation of the E test system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole. J Antimicrob Chemother (1995) 1.72
Fluconazole disk diffusion susceptibility testing of Candida species. J Clin Microbiol (1998) 1.72
Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol (2002) 1.72
Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol (1999) 1.71
Blue-fluorescent antibodies. Science (2000) 1.71
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother (2000) 1.68
Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis (1998) 1.66
Hypoparathyroidism and T cell immune defect in a patient with 10p deletion syndrome. J Pediatr (1986) 1.65
In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis (1999) 1.62
Comparative evaluation of macrodilution and chromogenic agar screening for determining fluconazole susceptibility of Candida albicans. J Clin Microbiol (1996) 1.61
Paecilomyces lilacinus infection in a liver transplant patient: case report and review of the literature. Transpl Infect Dis (2007) 1.60
Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis (1992) 1.58
Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med (2000) 1.58
Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol (2007) 1.58
Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol (1990) 1.57
Extraintestinal rotavirus infections in children with immunodeficiency. J Pediatr (1992) 1.56
Ocular penetration and pharmacokinetics of topical fluconazole. Cornea (1997) 1.56
Importance of Candida species other than Candida albicans as opportunistic pathogens. Med Mycol (1998) 1.55
Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant (2006) 1.55
Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol (2007) 1.55
Scedosporium inflatum, an emerging pathogen. J Clin Microbiol (1988) 1.54
Bioassays for itraconazole blood levels: an interlaboratory collaborative study. J Antimicrob Chemother (1999) 1.52
Phylogenetic analysis of Xylaria based on nuclear ribosomal ITS1-5. 8S-ITS2 sequences. FEMS Microbiol Lett (2000) 1.52
Assessment of reproductive disorders and birth defects in communities near hazardous chemical sites. II. Female reproductive disorders. Reprod Toxicol (1997) 1.50
Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother (2000) 1.48
Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis (1994) 1.46
Elucidating the origins of nosocomial infections with Candida albicans by DNA fingerprinting with the complex probe Ca3. J Clin Microbiol (1999) 1.44
Spectrum of clinically relevant Exophiala species in the United States. J Clin Microbiol (2007) 1.44